Corporate actions
Oct 04, 2023

Novartis AG : Demerger / Name change - update on 02-October-2023

Update on 02-October-2023 - updated ISINs are marked in bold in the table.


The company Novartis has announced on 18 August 2023 a spinoff of its Generics and Biosimilars business as an independent company under the name Sandoz Group. Shareholders of Novartis shall be entitled to receive for every 5 Novartis-shares 1 shares of the new company.

More information about this transaction is available on the company`s website.

The spinoff will result in an adjustment of the above mentioned contracts.

Update on 04-October-2023

Due to no open interest in NOVP,  the underlying security ISIN of the product is changed back from DE000A3EVDT4 to CH0012005267. These contracts continue to refer to Novartis AG shares only. No successor contracts will be introduced.

 

Market Status

XEUR

The market status window is an indication regarding the current technical availability of the trading system. It indicates whether news board messages regarding current technical issues of the trading system have been published or will be published shortly.

Please find further information about incident handling in the Emergency Playbook published on the Eurex webpage under Support --> Emergencies and safeguards. Detailed information about incident communication, market re-opening procedures and best practices for order and trade reconciliation can be found in the chapters 4.2, 4.3 and 4.5, respectively. Concrete information for the respective incident will be published during the incident via newsboard message. 

We strongly recommend not to take any decisions based on the indications in the market status window but to always check the production news board for comprehensive information on an incident.

An instant update of the Market Status requires an enabled up-to date Java™ version within the browser.